Cargando…

Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant

Detalles Bibliográficos
Autores principales:	Lopez, Laura, Burgner, David, Glover, Catherine, Carr, Jeremy, Clark, Julia, Boast, Alison, Vasilunas, Nan, McMullan, Brendan, Francis, Joshua R., Bowen, Asha C., Blyth, Christopher C., Macartney, Kristine, Crawford, Nigel W., Carey, Emma, Wood, Nicholas, Britton, Philip N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541565/ https://www.ncbi.nlm.nih.gov/pubmed/36237982 http://dx.doi.org/10.1016/j.lanwpc.2022.100604

Ejemplares similares

Corrigendum to “Lower risk of multi-system Inflammatory Syndrome in Children (MIS-C) with the Omicron variant” [The Lancet Regional Health - Western Pacific 27 (2022) 100604]
por: Lopez, Laura, et al.
Publicado: (2023)

Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5–15 years in Australia
por: Wood, Nicholas, et al.
Publicado: (2023)

Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: a national cohort study
por: Wurzel, Danielle, et al.
Publicado: (2021)

Testing for SARS-CoV-2 infection: a key strategy to keeping schools and universities open
por: Koirala, Archana, et al.
Publicado: (2021)

Addressing fundamental questions on MIS-C
por: Davies, Patrick
Publicado: (2021)

COVID‐19 in New South Wales children during 2021: severity and clinical spectrum
por: Williams, Phoebe, et al.
Publicado: (2022)

Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs
por: Crosby, Laura, et al.
Publicado: (2021)

Omicron severity: milder but not mild
por: Nealon, Joshua, et al.
Publicado: (2022)

Electronic patient-reported outcomes in chronic kidney disease
por: Anderson, Nicola, et al.
Publicado: (2022)

Omicron in pregnancy: time to breathe easier?
por: Auger, Nathalie, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

257. A Whole of Country Analysis of Antimicrobial Stewardship Resources, Activities, and Barriers for Children in Hospitals in Australia
por: Bryant, Penelope, et al.
Publicado: (2018)

Mis-Genotyping of Some Hepatitis D Virus Genotype 2 and 5 Sequences Using HDVdb
por: Charre, Caroline, et al.
Publicado: (2020)

IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2
por: Bassiri, Hamid, et al.
Publicado: (2022)

Omicron infection milder in nursing home residents
por: Katz, Morgan J, et al.
Publicado: (2022)

Prioritisation of COVID-19 boosters in the omicron era
por: Irving, Stephanie A, et al.
Publicado: (2022)

Milder disease with Omicron: is it the virus or the pre-existing immunity?
por: Sigal, Alex
Publicado: (2022)

Omicron: fewer adverse outcomes come with new dangers
por: Post, Lori Ann, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

Omicron breakthrough infections in patients with immune-mediated inflammatory diseases
por: Liew, Jean W, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

PIMS/MIS-C in der Omicron-Welle
por: Kerbl, Reinhold
Publicado: (2022)

Importance of understanding the reinfection risk of COVID-19 in children
por: Crawford, Nigel W
Publicado: (2022)

COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron
por: Hart, John D, et al.
Publicado: (2022)

CSF neopterin, a useful biomarker in children presenting with influenza associated encephalopathy?
por: Macdonald-Laurs, Emma, et al.
Publicado: (2019)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge
por: Belay, Ermias D, et al.
Publicado: (2022)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
por: Jin, Pengfei, et al.
Publicado: (2023)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
por: Yang, Su Lan, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

New year, new SARS-CoV-2 variant: Resolutions on genomic surveillance protocols to face Omicron
por: Oróstica, Karen Y., et al.
Publicado: (2022)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Shedding new light on COVID-19 therapeutics during the omicron era: a deeper dive into real-world data
por: De Vito, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i77qui5uq5nb7ch2uqiojg7r8e